Monday, May 6, 2024
Home Superbug News - CoronaVirus Watch List Page 5

Superbug News - CoronaVirus Watch List

    The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.

    Featured posts
    Cyclophilin, Biotech Stock Review

    Adding Hepion Pharma (HEPA) $1.73 to Watch List.

    Biotech News Editor / Curator -
    Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here? Oh my…and Oh boy....
    Internet Stock Review

    Newsletter: Institutional Analyst. And Yes, We Have Another Double.

    Institutional Analyst Newsletter Editor / Curator -
    1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....

    Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.

    2020 Watch List Editor / Curator -
    Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary...
    Dalrada

    Dalrada (DFCO) Finally Pops. Up 59% Today.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    Up 59% today on news and with 4 million shares trading and counting! LIVE QUOTE
    cITIUS

    Citius (CTXR) Announces Results of Mino-Lok Study.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    "Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
    Dyadic, Biotech Stock Review

    Dyadic (DYAI) Price Target $12.

    2020 Watch List Editor / Curator -
    Dalrada, Biotech Stock Review

    Dalrada (DFCO) Announces Form S-1 Registration Declared Effective by SEC

    Incubator Editor / Curator -
    SAN DIEGO , Nov. 3, 2020 /PRNewswire/ -- Dalrada Financial Corp. (OTC Pink: DFCO), is pleased to announce that its Form S-1 registration statement has been declared...
    Hepion, Biotech Stock Review

    Hepion Pharma (HEPA): News Archive

    CoronaVirus Editor / Curator -
    UPDATED CONTINUOUSLY.. 12/31/2020: News, As Huge As It Gets, From Hepion Pharma (HEPA) $2.10. 12/23/2020: Remember...
    CB Scientific, Biotech Stock Review

    Adding Telehealth Play CB Scientific (CBSC) $1.10 to CoronaVirus Watch List.

    Telehealth Editor / Curator -
    MyCardia's My-Cam Offers At-Home Heart Rate Monitoring. LIVE QUOTE

    Shark Tanks’ Kevin Harrington Gets Into Sanitizer Business.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    Aphex BioCleanse Systems Welcomes Original Shark Tank Investor Kevin Harrington and World-Renowned Entrepreneur Mark Timm as Advisors
    1...456...12Page 5 of 12

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.